Global Bispecific Antibodies Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Bispecific Antibodies Market Research Report 2024
A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
According to Mr Accuracy reports’s new survey, global Bispecific Antibodies market is projected to reach US$ 4147.6 million in 2034, increasing from US$ 3266 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bispecific Antibodies market research.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bispecific Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche Holding AG
GenScript
Sino Biological Inc.
Creative-Biolabs
AbbVie Inc.
Kymab
AstraZeneca
BIOCYTOGEN
Amgen Inc.
Pfizer Inc.
Novartis AG
Johnson & Johnson
ProteoGenix
Segment by Type
Blinatumab
Catumaxomab
Duligotumab
Cancer
Infectious Disease
Inflammatory and Autoimmune Disorders
CNS Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Bispecific Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Bispecific Antibodies market is projected to reach US$ 4147.6 million in 2034, increasing from US$ 3266 million in 2022, with the CAGR of 3.4% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bispecific Antibodies market research.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Bispecific Antibodies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche Holding AG
GenScript
Sino Biological Inc.
Creative-Biolabs
AbbVie Inc.
Kymab
AstraZeneca
BIOCYTOGEN
Amgen Inc.
Pfizer Inc.
Novartis AG
Johnson & Johnson
ProteoGenix
Segment by Type
Blinatumab
Catumaxomab
Duligotumab
Segment by Application
Cancer
Infectious Disease
Inflammatory and Autoimmune Disorders
CNS Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Bispecific Antibodies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source